{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:13:47Z","timestamp":1788844427672,"version":"build-2803163510"},"reference-count":91,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Systemic sclerosis is a systemic autoimmune rheumatic disease characterized by immune abnormalities, leading to vasculopathy and fibrosis. Autoantibody testing has become an increasingly important part of diagnosis and prognostication. Clinicians have been limited to antinuclear antibody (ANA), antitopoisomerase I (also known as anti-Scl-70) antibody, and anticentromere antibody testing. Many clinicians now have improved access to an expanded profile of autoantibody testing. In this narrative review article, we review the epidemiology, clinical associations, and prognostic value of advanced autoantibody testing in people with systemic sclerosis.<\/jats:p>","DOI":"10.3390\/diagnostics13050851","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T03:56:58Z","timestamp":1677124618000},"page":"851","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Advanced Autoantibody Testing in Systemic Sclerosis"],"prefix":"10.3390","volume":"13","author":[{"given":"Kholoud","family":"Almaabdi","sequence":"first","affiliation":[{"name":"Toronto Scleroderma Program, Division of Rheumatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON M5T 1R8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zareen","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Toronto Scleroderma Program, Division of Rheumatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON M5T 1R8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-2976","authenticated-orcid":false,"given":"Sindhu R.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Toronto Scleroderma Program, Division of Rheumatology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON M5T 1R8, Canada"},{"name":"Toronto Scleroderma Program, Schroeder Arthritis Institute, Division of Rheumatology,  Department of Medicine, Toronto Western Hospital, Toronto, ON M5T 379, Canada"},{"name":"Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON M5T 3M6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","volume":"55","author":"Distler","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00296-019-04315-7","article-title":"Correlation between circulating fibrocytes and dermal thickness in limited cutaneous systemic sclerosis patients: A pilot study","volume":"39","author":"Ruaro","year":"2019","journal-title":"Rheumatol. Int."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Caforio, A.L.P., De Luca, G., Baritussio, A., Seguso, M., Gallo, N., Bison, E., Cattini, M.G., Pontara, E., Gargani, L., and Pepe, A. (2021). Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. Diagnostics, 11.","DOI":"10.3390\/diagnostics11112165"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ruaro, B., Baratella, E., Confalonieri, P., Wade, B., Marrocchio, C., Geri, P., Busca, A., Pozzan, R., Andrisano, A.G., and Cova, M.A. (2021). High-Resolution Computed Tomography: Lights and Shadows in Improving Care for SSc-ILD Patients. Diagnostics, 11.","DOI":"10.3390\/diagnostics11111960"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1093\/rheumatology\/keab190","article-title":"Incidence and prevalence of systemic sclerosis globally: A comprehensive systematic review and meta-analysis","volume":"60","author":"Bairkdar","year":"2021","journal-title":"Rheumatology"},{"key":"ref_6","first-page":"1117","article-title":"Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases","volume":"33","author":"Johnson","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Benyamine, A., Bertin, D., Resseguier, N., Heim, X., Bermudez, J., Launay, D., Dubucquoi, S., Hij, A., Farge, D., and Lescoat, A. (2021). Quantification of Antifibrillarin (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis. Diagnostics, 11.","DOI":"10.3390\/diagnostics11061064"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3899\/jrheum.121089","article-title":"Progression of nailfold microvascular damage and antinuclear antibody pattern in systemic sclerosis","volume":"40","author":"Sulli","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/01.bor.0000245726.33006.c3","article-title":"Is scleroderma an autoantibody mediated disease?","volume":"18","author":"Arnett","year":"2006","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jclinepi.2013.12.009","article-title":"Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria","volume":"67","author":"Johnson","year":"2014","journal-title":"J. Clin. Epidemiol"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: An American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"Khanna","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13075-017-1243-y","article-title":"Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis","volume":"19","author":"Wither","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13075-018-1752-3","article-title":"The presence of anti-nuclear antibodies alone is associated with changes in B cell activation and T follicular helper cells similar to those in systemic autoimmune rheumatic disease","volume":"20","author":"Baglaenko","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/rheumatology\/keab501","article-title":"Serological abnormalities that predict progression to systemic autoimmune rheumatic diseases in antinuclear antibody-positive individuals","volume":"61","author":"Prokopec","year":"2022","journal-title":"Rheumatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"886442","DOI":"10.3389\/fimmu.2022.886442","article-title":"Altered Balance of Pro-Inflammatory Immune Cells to T Regulatory Cells Differentiates Symptomatic From Asymptomatic Individuals With Anti-Nuclear Antibodies","volume":"13","author":"Gupta","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13075-019-2013-9","article-title":"Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease","volume":"21","author":"Hafiz","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_18","first-page":"24","article-title":"Variability of tissue-localizing properties of serum from patients with different disease states","volume":"2","author":"Fennell","year":"1962","journal-title":"Lab. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0140-6736(63)92920-9","article-title":"Antinuclear and precipitating autoantibodies in progressive systemic sclerosis","volume":"2","author":"Beck","year":"1963","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/art.10561","article-title":"Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing","volume":"47","author":"Solomon","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/acr.23292","article-title":"Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data","volume":"70","author":"Leuchten","year":"2018","journal-title":"Arthritis Care. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jalm\/jfab140","article-title":"The International Consensus on ANA Patterns (ICAP) in 2021-The 6th Workshop and Current Perspectives","volume":"7","author":"Chan","year":"2022","journal-title":"J. Appl. Lab. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/art.22043","article-title":"Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I\/III antibodies","volume":"54","author":"Yamasaki","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/rheumatology\/ken201","article-title":"Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA","volume":"47","author":"Parker","year":"2008","journal-title":"Rheumatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/art.11113","article-title":"Evidence-based guidelines for the use of immunologic tests: Anticentromere, Scl-70, and nucleolar antibodies","volume":"49","author":"Reveille","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0002-9343(97)00023-5","article-title":"Test performance in systemic sclerosis: Anti-centromere and anti-Scl-70 antibodies","volume":"103","author":"Alter","year":"1997","journal-title":"Am. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kep290","article-title":"Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay","volume":"48","author":"Satoh","year":"2009","journal-title":"Rheumatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_29","first-page":"1288","article-title":"AB0673\u2005Testing for antibodies specific to fibrillarin (U3 RNP) shows added value for diagnosis of systemic sclerosis","volume":"76","author":"Gehring","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3899\/jrheum.160574","article-title":"Antifibrillarin Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis","volume":"44","author":"Assassi","year":"2017","journal-title":"J. Rheumatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/BOR.0000000000000325","article-title":"Progress in understanding the diagnostic and pathogenic role of autoantibodies associated with systemic sclerosis","volume":"28","author":"Choi","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4236\/ojra.2013.32017","article-title":"Associations with Organ Involvement and Autoantibodies in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group (CSRG)*","volume":"3","author":"Tangri","year":"2013","journal-title":"Open J. Rheumatol. Autoimmune Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1756-185X.2011.01688.x","article-title":"South Australian Scleroderma Register: Autoantibodies as predictive biomarkers of phenotype and outcome","volume":"15","author":"Graf","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/03009742.2021.1887927","article-title":"Anti-Ro52\/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients","volume":"50","author":"Lee","year":"2021","journal-title":"Scand. J. Rheumatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.autrev.2010.05.020","article-title":"Anti-Ku antibodies: Clinical, genetic and diagnostic insights","volume":"9","author":"Belizna","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"A654","DOI":"10.1136\/annrheumdis-2013-eular.1943","article-title":"SAT0217\u2005Anti- RO\/SSA Antibodies in Systemic Sclerosis: Frequency and Clinical Associations in a Monocentric Referral Cohort","volume":"72","author":"Breda","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105048","DOI":"10.1016\/j.jbspin.2020.06.021","article-title":"Extended myositis-specific and -associated antibodies profile in systemic sclerosis: A cross-sectional study","volume":"88","author":"Leurs","year":"2021","journal-title":"Joint Bone Spine"},{"key":"ref_38","first-page":"1543","article-title":"Autoantibodies to NOR 90\/hUBF: Longterm clinical and serological followup in a patient with limited systemic sclerosis suggests an antigen driven immune response","volume":"29","author":"Dagher","year":"2002","journal-title":"J. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1093\/rheumatology\/keab575","article-title":"Clinical significance of anti-NOR90 antibodies in systemic sclerosis and idiopathic interstitial pneumonia","volume":"61","author":"Yamashita","year":"2021","journal-title":"Rheumatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/art.41560","article-title":"Anti-Th\/To Antibodies: Association With Lung Disease and Potential Protection From Systemic Sclerosis-Related Cancer? Comment on the Article by Mecoli et al","volume":"73","author":"Mahler","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2015.00167","article-title":"Autoantibodies in systemic sclerosis: Unanswered questions","volume":"6","author":"Kayser","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/ard.2007.073981","article-title":"Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: A European EUSTAR-initiated multi-centre case-control study","volume":"67","author":"Rozman","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_43","first-page":"80","article-title":"The clinical relevance of autoantibodies in scleroderma","volume":"5","author":"Ho","year":"2003","journal-title":"Arthritis Res. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.autrev.2012.07.005","article-title":"Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis","volume":"12","author":"Villalta","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3899\/jrheum.180042","article-title":"Ethnic Variations in Systemic Sclerosis Disease Manifestations, Internal Organ Involvement, and Mortality","volume":"46","author":"Ahmad","year":"2019","journal-title":"J. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.3899\/jrheum.170953","article-title":"Epidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome","volume":"45","author":"Alharbi","year":"2018","journal-title":"J. Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3899\/jrheum.201594","article-title":"Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets","volume":"48","author":"Nevskaya","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_48","first-page":"1855","article-title":"Classification criteria for systemic sclerosis subsets","volume":"34","author":"Johnson","year":"2007","journal-title":"J. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3899\/jrheum.201299","article-title":"Epidemiology and Treatment of Peripheral Neuropathy in Systemic Sclerosis","volume":"48","author":"AlMehmadi","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/art.38219","article-title":"Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis","volume":"66","author":"Sobanski","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/sji.12510","article-title":"The Clinical Relevance of Antifibrillarin (anti-U3-RNP) Autoantibodies in Systemic Sclerosis","volume":"85","author":"Tall","year":"2017","journal-title":"Scand. J. Immunol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1346-8138.2009.00762.x","article-title":"Autoantibody profiles in systemic sclerosis: Predictive value for clinical evaluation and prognosis","volume":"37","author":"Hamaguchi","year":"2010","journal-title":"J. Dermatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1002\/art.34482","article-title":"A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis","volume":"64","author":"Steen","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Cavazzana, I., Vojinovic, T., Airo\u2019, P., Fredi, M., Ceribelli, A., Pedretti, E., Lazzaroni, M.G., Garrafa, E., and Franceschini, F. (2022). Systemic Sclerosis-Specific Antibodies: Novel and Classical Biomarkers. Clin. Rev. Allergy Immunol., 1\u201319.","DOI":"10.1007\/s12016-022-08946-w"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.10760","article-title":"A comparison between anti-Th\/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement","volume":"48","author":"Mitri","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/art.42152","article-title":"Development of Pulmonary Hypertension in Over One-Third of Patients With Th\/To Antibody-Positive Scleroderma in Long-Term Follow-U","volume":"74","author":"Suresh","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"ref_57","first-page":"1276","article-title":"The low-abundance U11 and U12 small nuclear ribonucleoproteins (snRNPs) interact to form a two-snRNP complex","volume":"12","author":"Wassarman","year":"1992","journal-title":"Mol. Cell. Biol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/art.24586","article-title":"Anti-U11\/U12 RNP antibodies in systemic sclerosis: A new serologic marker associated with pulmonary fibrosis","volume":"61","author":"Fertig","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/rheumatology\/keab279","article-title":"Anti-RNPC-3 antibody predicts poor prognosis in patients with interstitial lung disease associated to systemic sclerosis","volume":"61","author":"Severino","year":"2021","journal-title":"Rheumatology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6004","DOI":"10.1093\/emboj\/cdg592","article-title":"Bicaudal D induces selective dynein-mediated microtubule minus end-directed transport","volume":"22","author":"Hoogenraad","year":"2003","journal-title":"Embo. J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.autrev.2010.09.005","article-title":"Clinical and laboratory aspects of Ro\/SSA-52 autoantibodies","volume":"10","author":"Defendenti","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/mr\/roab118","article-title":"Anti-Ro\/SS-A antibody is associated with worse pulmonary outcome and reduced overall survival in systemic sclerosis","volume":"32","author":"Meridor","year":"2022","journal-title":"Mod. Rheumatol."},{"key":"ref_63","first-page":"S131","article-title":"Monospecific anti-Ro52\/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: Evidence of an association with interstitial lung disease and worse survival","volume":"33","author":"Wodkowski","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/annrheumdis-2013-204487","article-title":"Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis","volume":"74","author":"Moinzadeh","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"ref_65","first-page":"118","article-title":"A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies","volume":"31","author":"Cavazzana","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e4713","DOI":"10.1097\/MD.0000000000004713","article-title":"Single-specificity anti-Ku antibodies in an international cohort of 2140 systemic sclerosis subjects: Clinical associations","volume":"95","author":"Hoa","year":"2016","journal-title":"Medicine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1084\/jem.176.4.973","article-title":"Cloning and characterization of the cDNA coding for a polymyositis-scleroderma overlap syndrome-related nucleolar 100-kD protein","volume":"176","author":"Bautz","year":"1992","journal-title":"J. Exp. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/08916934.2015.1077231","article-title":"Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects","volume":"48","author":"Wodkowski","year":"2015","journal-title":"Autoimmunity"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/annrheumdis-2021-eular.1477","article-title":"AB0427\u2005ANTI-NOR90 autoantibodies: Favorable or unfavorable prognosis?","volume":"80","author":"Valero","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/annrheumdis-2022-eular.1636","article-title":"POS0863\u2005ANTI-NOR90 antibodies in the setting of connective tissue disease: Clinical significance and comparison with a cohort of patients with systemic sclerosis","volume":"81","author":"Biglia","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"key075-428","DOI":"10.1093\/rheumatology\/key075.428","article-title":"204 A lost-to-follow-up autoantibody for the diagnosis of autoimmune disease: Prevalence and clinical characteristics of anti-NOR90\/hUBF positive patients","volume":"57","author":"Koutsianas","year":"2018","journal-title":"Rheumatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.15252\/embj.201591245","article-title":"RuvbL1 and RuvbL2 enhance aggresome formation and disaggregate amyloid fibrils","volume":"34","author":"Zaarur","year":"2015","journal-title":"Embo. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/acr.22163","article-title":"Autoantibodies to RuvBL1 and RuvBL2: A novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement","volume":"66","author":"Kaji","year":"2014","journal-title":"Arthritis Care Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/bdrc.10030","article-title":"Biology of platelet-derived growth factors in development","volume":"69","author":"Betsholtz","year":"2003","journal-title":"Birth Defects Res. C Embryo Today"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1056\/NEJMoa052955","article-title":"Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis","volume":"354","author":"Baroni","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: An important tool to support diagnosis of myositis","volume":"280","author":"Betteridge","year":"2016","journal-title":"J. Intern. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"898083","DOI":"10.3389\/fgene.2022.898083","article-title":"Signal Recognition Particle in Human Diseases","volume":"13","author":"Kellogg","year":"2022","journal-title":"Front. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1136\/annrheumdis-2017-212915","article-title":"Detection of myositis-specific antibodies","volume":"78","author":"Vulsteke","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/08916934.2021.1907842","article-title":"Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests","volume":"54","author":"Alkema","year":"2021","journal-title":"Autoimmunity"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"11212","DOI":"10.1038\/s41598-022-15062-4","article-title":"Combinations of scleroderma hallmark autoantibodies associate with distinct clinical phenotypes","volume":"12","author":"Clark","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.61.2.121","article-title":"Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis","volume":"61","author":"Dick","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_85","first-page":"96","article-title":"Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: A EUSTAR group-based study","volume":"31","author":"Heijnen","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/03009742.2017.1299793","article-title":"There is a need for new systemic sclerosis subset criteria. A content analytic approach","volume":"47","author":"Johnson","year":"2018","journal-title":"Scand. J. Rheumatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/BOR.0000000000000443","article-title":"Progress in the clinical classification of systemic sclerosis","volume":"29","author":"Johnson","year":"2017","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/ard.2010.136929","article-title":"Preliminary criteria for the very early diagnosis of systemic sclerosis: Results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group","volume":"70","author":"Avouac","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5301\/jsrd.5000198","article-title":"Systemic Sclerosis Trial Design Moving Forward","volume":"1","author":"Johnson","year":"2016","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"298","DOI":"10.5301\/jsrd.5000212","article-title":"Subsets in systemic sclerosis: One size does not fit all","volume":"1","author":"Leclair","year":"2016","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.5152\/eurjrheum.2020.19116","article-title":"Systemic sclerosis: To subset or not to subset, that is the question","volume":"7","author":"Johnson","year":"2020","journal-title":"Eur. J. Rheumatol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/5\/851\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:40:06Z","timestamp":1760121606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/5\/851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":91,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["diagnostics13050851"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13050851","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]}}}